-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
NewLikelihood of Approval Analysis for Drug Toxicity
Overview How likely is it that the drugs in Drug Toxicity will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Drug Toxicity Overview Drug toxicity' can be defined as a diverse array...
-
Thematic Analysis
NewGeneric Drugs – Physician Perspective – Thematic Intelligence
Reasons to buy the ‘Generic Drugs – Physician Perspective’ thematic intelligence report: Assess healthcare professionals’ attitudes towards generic drugs prescription. Better understand the barriers to the production and uptake of generic medicines. Capture physicians’ opinions on generics substitution. Better understand patients’ preferences. Assess past and future generics uptake. Gain a better understanding of cost consideration when prescribing drugs. Explore the differences across markets. How is our ‘Generic Drugs – Physician Perspective’ report unique from other reports in the market? This...
-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
NewLikelihood of Approval Analysis for Substance (Drug) Abuse
Overview How likely is it that the drugs in Substance (Drug) Abuse will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Substance (Drug) Abuse Overview Substance abuse refers to the problematic pattern...
-
Sector Analysis
NewFriedreich Ataxia (FRDA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in FRDA therapeutics. - More than 54,000 diagnosed prevalent cases of FRDA are anticipated in 2024 in the 16 countries covered in GlobalData’s epidemiology forecast for FRDA. - The marketed drugs space for FRDA is limited to just two approved drugs, Biogen's Skyclarys (omaveloxolone) is the leading drug in FRDA space. - R&D efforts in the FRDA space are limited, with no pre-registration drugs currently in the...
-
Track & Monitor
Innovation in pharma: phenotypic drug screening
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s phenotypic drug screening segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Sector Analysis
NewPost-Operative Pain (POP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in POP therapeutics. - In 2024, more than 34,000,000 incident cases of POP are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for POP. - Most marketed drugs for POP are enzyme inhibitors, followed by receptor agonists, by mechanism of action. - Phase III pipeline for POP is robust and includes 27 drugs, while pre-registration comprises four drugs. - Approximately 39.34% of the clinical trials...
-
Sector Analysis
NewResistant Hypertension (RH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in RH therapeutics. - GlobalData epidemiologists estimated more than 79 million diagnosed prevalent cases of RH in 2023 in the 16 countries covered in GlobalData’s epidemiology forecast for RH. - The marketed drugs space for RH is dominated by off-label antihypertensive therapies. - The R&D activity is limited within the RH space, with only three molecules present in the late-stage pipeline.. - The US is emerging as...